A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis

New England Journal of Medicine

Volumn 375, Issue 7, 2016, Pages 631-643

  Nevens, F ^a   Andreone, P ^b   Mazzella, G ^b   Strasser, S I ^f   Bowlus, C ^g   Invernizzi, P ^c,d   Drenth, J P H ^j   Pockros, P J ^h   Regula, J ⁿ   Beuers, U ^k   Trauner, M ^o   Jones, D E ^p   Floreani, A ^e   Hohenester, S ^r   Luketic, V ^s   Shiffman, M ^t   Van Erpecum, K J ^l   Vargas, V ^u   Vincent, C ^v   Hirschfield, G M ^q   Shah, H ^w   Hansen, B ^m   Lindor, K D ^x   Marschall, H U ^y   Kowdley, K V ^z   Hooshmand Rad, R ⁱ   Marmon, T ⁱ   Sheeron, S ⁱ   Pencek, R ⁱ   MacConell, L ⁱ   Pruzanski, M ⁱ   Shapiro, D ⁱ   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SCRIPPS CLINIC   (United States)

ⁱ INTERCEPT PHARMACEUTICALS   (United States)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^r UNIVERSITY OF MUNICH   (Germany)

^s VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^t Liver Institute of Virginia   (United States)

^u INSTITUTO DE SALUD CARLOS III   (Spain)

^v CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^w TORONTO WESTERN HOSPITAL   (Canada)

^x ARIZONA STATE UNIVERSITY   (United States)

^y UNIVERSITY OF GOTHENBURG   (Sweden)

^z SWEDISH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUTOTAXIN; BILIRUBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBETICHOLIC ACID; PLACEBO; URSODEOXYCHOLIC ACID; 6-ETHYLCHENODEOXYCHOLIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; BLOOD; BONE DENSITY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ALKALINE PHOSPHATASE; BILE ACIDS AND SALTS; BONE DENSITY; CHENODEOXYCHOLIC ACID; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PRURITUS;

EID: 84982102773     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509840     Document Type: Conference Paper

References (32)

1. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis.' Dig Liver Dis 2015; 47: 924-6.
2. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis.' Hepatology 2015; 62: 1620-2.
3. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis.' Gut 2015; 64: 1671-2.
4. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis.' J Hepatol 2015; 63: 1285-7.
5. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis.' Gastroenterology 2015; 149: 1627-9.
6. Kim WR, Lindor KD, Locke GR III, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119: 1631-6.
7. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
9. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144(3): 560-569.e7.
10. Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study. Gastroenterology 2014; 147(6): 1338-49.e5.
11. Pellicciari R, Fiorucci S, Camaioni E, et al. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569-72.
12. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-91.
13. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bileacid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-93.
14. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non- Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo- controlled trial. Lancet 2015; 385: 956-65.
15. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: Suppl: S25-S37.
16. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148(4): 751- 61.e8.
17. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long- Term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
18. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208.
19. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59: 236-42.
20. Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 2005; 54: 1622-9.
21. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: Evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.
22. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: A new measure of pruritus. Br J Dermatol 2010; 162: 587-93.
23. Murtaugh PA, Dickson ER, Van Dam GM, et al. Primary biliary cirrhosis: prediction of short- Term survival based on repeated patient visits. Hepatology 1994; 20: 126-34.
24. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
25. Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139: 1008-18.
26. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-97.
27. Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360: 2544-55.
28. Neuman M, Angulo P, Malkiewicz I, et al. Tumor necrosis factor- Alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196-202.
29. Bolier AR, Peri S, Oude Elferink RP, Beuers U. The challenge of cholestatic pruritus. Acta Gastroenterol Belg 2012; 75: 399-404.
30. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29: 1003-6.
31. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51: 265-9.
32. Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 2010; 285: 3035-43.